Acute lymphoblastic leukemia-derived dendritic cells express tumor associated antigens: PNPT1, PMPCB, RHAMM, BSG and ERCC1

Neoplasma

Volumn 56, Issue 5, 2009, Pages 428-434

  Luczynski W ^a   Kowalczuk, O ^a   Stasiak Barmuta, A ^a   Ilendo, E ^a   Krawczuk Rybak, M ^a   Chyczewski, L ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute lymphoblastic leukemia; Children; Dendritic cells; Immunotherapy; Tumor associated antigens

Indexed keywords

BSG ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; ERCC1 ANTIGEN; INTERLEUKIN 4; MESSENGER RNA; PMPCB ANTIGEN; PNPT1 ANTIGEN; RHAMM ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; BSG PROTEIN, HUMAN; CD147 ANTIGEN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; EXORIBONUCLEASE; HERMES ANTIGEN; HYALURONAN MEDIATED MOTILITY RECEPTOR; HYALURONAN-MEDIATED MOTILITY RECEPTOR; METALLOPROTEINASE; MITOCHONDRIAL PROCESSING PEPTIDASE; PNPT1 PROTEIN, HUMAN; SCLEROPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL STIMULATION; CELL TRANSFORMATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PRESCHOOL CHILD;

ANTIGENS, CD147; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CD40 LIGAND; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DNA-BINDING PROTEINS; ENDONUCLEASES; EXORIBONUCLEASES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; MALE; METALLOENDOPEPTIDASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, MESSENGER;

EID: 69849105211     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_05_428     Document Type: Article

References (36)

1. DUNCAN C, RODDIE H. Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol 2008; 21: 521-541. doi:10.1016/j.beha.2008.07.010
2. ŁUCZYŃSKI W, STASIAK-BARMUTA A, IŁENDO E, et al. CD40 stimulation induces differentiationofacutelymphoblasticleukemia cells into dendritic cells. Acta Biochim Pol 2006; 53: 377-382.
3. D'AMICO G, VULCANO M, BUGARIN C, et al. CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12 defective APCs that induce allogeneic T-cell anergy. Blood 2004; 104: 744-751. doi:10.1182/blood-2003-11-3762 PMid:15001471
4. D'AMICO G, MARIN V, BIONDI A. Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2004; 17: 465-477. doi:10.1016/j.beha.2004.05.011
5. LEE J, SAIT SN, WETZLER M. Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts. Int Immunol 2004; 16: 1377-1389. doi:10.1093/intimm/dxh139 PMid:15302850
6. CIGNETTI A, BRYANT E, ALLIONE B, et al. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999; 94: 2048-2055.
7. GREINER J, DOHNER H, SCHMITT M. Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006; 91: 1653-1661.
8. GIANNOPOULOS K, LI L, BOJARSKA-JUNAK A, et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 2006; 29: 95-103.
9. NIEMEYER P, TURECI O, EBERLE T, et al. Expression of serologically identified tumor antigens in acute leukemias. Leuk Res 2003; 27: 655-660. doi:10.1016/S0145-2126(02)00230-8 PMid:12681366
10. REZVANI K, YONG AS, MIELKE S, et al. Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242. doi:10.1182/blood-2007-08- 108241 PMid:17875804
11. GREINER J, RINGHOFFER M, TANIGUCHI M, et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003; 106: 224-231. doi:10.1002/ijc.11200
12. LIN YW, KUBOTA M, KOISHI S, et al. Analysis of mutations at the DNA repair genes in acute childhood leukaemia. Br J Haematol 1998; 103: 462-466. doi:10.1046/j.1365-2141.1998.00973.x PMid:9827920 (Pubitemid 28522454)
13. MAYR C, KOFLER DM, BUNING H, et al. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 2005; 106: 3223-3226. doi:10.1182/blood-2005-04-1742 PMid:16014560
14. LI L, REINHARDT P, SCHMITT A, et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 2005; 54: 685-693. doi:10.1007/s00262-004-0631-8
15. LIVAK KJ, SCHMITTGEN TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ddCT method. Methods 2001; 25: 402-408. doi:10.1006/meth.2001.1262 PMid:11846609 (Pubitemid 34164012)
16. ŁUCZYŃSKI W, KOWALCZUK O, IŁENDO E, et al. Upregulation of antigen-processing machinery components at mRNA level in acute lymhpoblastic leukemia cells after CD40 stimulation. Ann Hematol 2007; 86: 339-345. doi:10.1007/s00277-007-0256-z PMid:17285277
17. GREINER J, SCHMITT M, LI L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117. doi:10.1182/blood-2006-01-023127 PMid:16931630
18. STEINBACH D, VIEHMANN S, ZINTL F, et al. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138: 89-91. doi:10.1016/S0165-4608(02)00582-4 PMid:12419593 (Pubitemid 35292607)
19. PAYDAS S, TANRIVERDI K, YAVUZ S, et al. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005; 79: 257-261. doi:10.1002/ajh.20425 PMid:16044453
20. SPANAKI A, PERDIKOGIANNI C, LINARDAKIS E, et al. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res 2007; 31: 639-642. doi:10.1016/j.leukres.2006.06.006 PMid:16860864 (Pubitemid 46559992)
21. STEINBACH D, SCHRAMM A, EGGERT A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006; 12: 2434-2441. doi:10.1158/1078-0432.CCR-05- 2552 PMid:16638849
22. QUINTARELLI C, DOTTI G, DE-ANGELIS B, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myloid leukemia. Blood 2008; 112: 1876-1885. doi:10.1182/blood-2008-04- 150045 PMid:18591381
23. BEESLEY AH, CUMMINGS AJ, FREITAS JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol 2005; 131: 447-456. doi:10.1111/j.1365-2141.2005.05785.x PMid:16281934
24. WANG SL, ZHAO H, ZHOU B, et al. Polymophisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res 2006; 30: 1341-1345. doi:10.1016/j.leukres.2006.03.027 PMid:16723154 (Pubitemid 44321911)
25. REZVANI K, YONG AS, SAVANI BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110: 1924-1932. doi:10.1182/blood-2007-03-076844 PMid:17505014 PMCid:1976363
26. REZVANI K, BRENCHLEY JM, PRICE DA, et al. T-cell responses directed against multiple HLA-A*201-restricted epitopes derived from Wilms'tumor1 protein in patients with leukemia and healthy donor: identification, quantification, and characterization. Clin Cancer Res 2005; 24: 8799-8807. doi:10.1158/1078-0432.CCR-05-1314 PMid:16361568
27. TAKAHASHI H, FURUKAWA T, YANO T, et al. Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral responses in leukemia patients. Exp Hematol 2007; 35: 1091-1099. doi:10.1016/j.exphem.2007.03.015 PMid:17588478
28. SCHMIDT SM, SCHAG K, MULLER MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-576. doi:10.1182/blood-2002-08-2554 PMid:12576330
29. MARTÍNEZ A, OLARTE I, MERGOLD MA, et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 2007; 31: 33-37. doi:10.1016/j.leukres. 2006.05.009 PMid:16806467 (Pubitemid 44709750)
30. HUBERT RS, VIVANCO I, CHEN E, et al. STEAP: a prostate- specific cell-surface antigen highly expressed in human prostate tumors. PNAS 1999; 96: 14523-14528. doi:10.1073/pnas.96.25.14523
31. BRUCHOVA H, KALINOVA M, BRDICKA R. Arraybased analysis of gene expression in childhood acute lymphoblastic leukemia. Leuk Res 2004; 28: 1-7. doi:10.1016/S0145-2126(03)00120-6 PMid:14630074 (Pubitemid 37433787)
32. MAYR C, BUND D, SCHLEE M, et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 2005; 105: 1566-1573. doi:10.1182/blood-2004-04-1233 PMid:15471955
33. OHMINAMI H, YASUKAWA M, FUJITA S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-293.
34. SCHMITT M, SCHMITT A, ROJEWSKI MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111: 1357-1365. doi:10.1182/blood-2007-07-099366 PMid:17978170
35. ROUSSEAU RF, BIAGI E, DUTOUR A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006; 107: 1332-1341. doi:10.1182/blood-2005-03-1259 PMid:16249392 PMCid:1895421
36. HAINING WN, CARDOSO AA, KECZKEMETHY HL, et al. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol 2005; 33: 286-294. doi:10.1016/j.exphem.2004.12.001 PMid:15730852